Wall Street brokerages expect Albireo Pharma Inc (NASDAQ:ALBO) to announce ($0.97) earnings per share for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Albireo Pharma’s earnings. The highest EPS estimate is ($0.68) and the lowest is ($1.08). Albireo Pharma posted earnings of ($0.73) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 32.9%. The company is scheduled to report its next quarterly earnings results on Tuesday, November 13th.

On average, analysts expect that Albireo Pharma will report full year earnings of ($3.39) per share for the current year, with EPS estimates ranging from ($3.70) to ($2.75). For the next financial year, analysts expect that the business will report earnings of ($3.95) per share, with EPS estimates ranging from ($6.06) to ($2.13). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Albireo Pharma.

Albireo Pharma (NASDAQ:ALBO) last released its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($1.22) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.98) by ($0.24). The company had revenue of $0.73 million for the quarter, compared to analysts’ expectations of $2.00 million.

A number of brokerages have recently issued reports on ALBO. ValuEngine upgraded shares of Albireo Pharma from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 2nd. BidaskClub cut shares of Albireo Pharma from a “sell” rating to a “strong sell” rating in a research note on Friday, May 4th. Wedbush restated an “outperform” rating and issued a $69.00 price objective on shares of Albireo Pharma in a research note on Tuesday, June 12th. Finally, Zacks Investment Research upgraded shares of Albireo Pharma from a “hold” rating to a “buy” rating and set a $36.00 price objective for the company in a research note on Tuesday, July 24th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $59.40.

In other news, COO Jan Mattsson sold 25,000 shares of the stock in a transaction on Wednesday, June 13th. The shares were sold at an average price of $32.26, for a total value of $806,500.00. Following the completion of the transaction, the chief operating officer now owns 43,538 shares in the company, valued at approximately $1,404,535.88. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Ronald Harold Wilfred Cooper bought 788 shares of the stock in a transaction dated Tuesday, August 14th. The stock was purchased at an average cost of $31.85 per share, for a total transaction of $25,097.80. The disclosure for this purchase can be found here. Corporate insiders own 3.60% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of the company. MetLife Investment Advisors LLC bought a new stake in shares of Albireo Pharma in the 2nd quarter worth about $167,000. Metropolitan Life Insurance Co. NY bought a new stake in shares of Albireo Pharma in the 2nd quarter worth about $118,000. DRW Securities LLC bought a new stake in shares of Albireo Pharma in the 2nd quarter worth about $320,000. Renaissance Technologies LLC grew its holdings in shares of Albireo Pharma by 16.2% in the 2nd quarter. Renaissance Technologies LLC now owns 107,366 shares of the biopharmaceutical company’s stock worth $3,811,000 after purchasing an additional 14,934 shares during the last quarter. Finally, Federated Investors Inc. PA grew its holdings in shares of Albireo Pharma by 89.1% in the 2nd quarter. Federated Investors Inc. PA now owns 586,146 shares of the biopharmaceutical company’s stock worth $20,808,000 after purchasing an additional 276,221 shares during the last quarter. 55.97% of the stock is currently owned by institutional investors and hedge funds.

NASDAQ:ALBO opened at $30.17 on Friday. The firm has a market cap of $372.59 million, a P/E ratio of -9.58 and a beta of 1.23. Albireo Pharma has a one year low of $20.25 and a one year high of $39.87.

About Albireo Pharma

Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.

Featured Story: Growth Stocks

Get a free copy of the Zacks research report on Albireo Pharma (ALBO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Albireo Pharma (NASDAQ:ALBO)

Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.